Articles tagged "Highly-sensitized"

2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Infectious Complications in Elderly Kidney Transplant Recipients Undergoing Desensitization
S. Sethi, R. Najjar, A. Peng, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Data is limited on the impact of desensitization on infectious complications in elderly kidney transplant (KT) recipients. We examined infectious complications in elderly KT…
2020 American Transplant Congress
Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity
V. Jucaud¹, A. Babu², D. Briggs³, N. Krishnan⁴, D. Mitchell⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³NHS Blood and Transplant, Birmingham, United Kingdom, ⁴University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁵University of Warwick Medical School, Coventry, United Kingdom
*Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…
2020 American Transplant Congress
Feasibility and Limitations of Desensitization Therapy in Highly Sensitized Pediatric ESRD Patients: A Single-Center Experience
J. Steggerda¹, H. Pizzo², X. Zhang³, J. Garrison², I. Kim¹, M. Haas⁴, A. Vo¹, S. Jordan¹, D. Puliyanda²
¹Comprehensive Transplant Center, Cedars-Sinai Med Ctr, West Hollywood, CA, ²Pediatric Nephrology, Cedars-Sinai Med Ctr, West Hollywood, CA, ³HLA Laboratory, Cedars-Sinai Med Ctr, West Hollywood, CA, ⁴Renal Pathology, Cedars-Sinai Med Ctr, West Hollywood, CA
*Purpose: There are a growing number of pediatric (peds) patients (pts) awaiting renal transplantation (tx) who are considered highly sensitized (HS). We report long-term outcomes…
2020 American Transplant Congress
Impact of Desensitization Strategies with Proteosome Inhibition and Costimulation Blockade on Xenoreactive Humoral Responses
B. P. Lovasik¹, A. J. Matar¹, D. A. Faber¹, D. V. Mathews¹, C. P. Breeden¹, S. C. Kim¹, A. J. Tector², A. B. Adams¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Miami, Miami, FL
*Purpose: “Delayed” antibody-mediated xenograft rejection is the one of the most important obstacles to clinical application of pig organ xenografts. The aim of this study…
2020 American Transplant Congress
Risk Stratification in Antibody Incompatible Kidney Transplantation: Can Aggressive Rejection be Avoided?
S. Punjala¹, M. Ibrahim¹, N. Vallant¹, N. Kessaris¹, O. Shaw², N. Mamode¹
¹Department of Nephrology, Renal Transplant and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ²Clinical Transplantation Laboratory, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
*Purpose: Our experience in antibody incompatible kidney transplantation, and anecdotal reports, suggest that a specific form of rejection, which we term Early Aggressive Antibody Mediated…
2020 American Transplant Congress
Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)
S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2020 American Transplant Congress
Assessment of Infectious Complications Following ABO-Blood Group Incompatible Renal Transplant
J. Banbury¹, T. Loosier¹, C. Lin², K. Gutierrez¹
¹University of Alabama at Birmingham Hospital, Birmingham, AL, ²Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL
*Purpose: In response to the ongoing organ shortage, ABO-incompatible (ABOi) renal transplant (RT) provides an alternative option for patients with end-stage kidney disease. Literature suggests…
2020 American Transplant Congress
High PRA Increases Rejection but Does Not Worsen Renal Function in the First Year Post Kidney Transplant with Alemtuzumab Induction
B. Wise, A. Freeman, M. Janusek, S. Anders, L. Hutchinson, U. Kaszubski, D. Marroquin, D. Martin, H. Bohorquez
Ochsner Medical Center, New Orleans, LA
*Purpose: Sensitization is an important immunologic risk factor considered in renal allograft allocation and influences immunosuppression. Unfortunately, there is a lack of consensus regarding the…
2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
N. Kamar¹, L. Couzi², L. Albano³, A. Durrbach⁴, V. Pernin⁵, L. Esposito¹, M. Lequintrec⁵, P. Merville², A. Del Bello¹
¹Toulouse University Hospital, Toulouse, France, ²Bordeaux University Hospital, Bordeaux, France, ³Nice University Hospital, Nice, France, ⁴Henri Mondor University Hospital, Paris, France, ⁵Montpellier University Hospital, Montpellier, France
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…